Read More Pharma Industry News FDA clears Mabwell’s next-gen ADC 7MW4911: What’s at stake in the global GI oncology race? Mabwell secures FDA IND for CDH17-targeting ADC 7MW4911, marking a major step in GI cancer therapy. Find out how this could reshape advanced oncology care. byPallavi MadhirajuAugust 20, 2025